The short version of Angiotensin IV analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-19. Anything still debated is marked as such rather than presented as settled.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
=== Laboratory automation === In research fields such as synthetic biology, where highly iterative experimentation is common, considerable efforts have been made to automate workflows. Digital microfluidics is often touted as a laboratory automation solution, with a number of advantages over alternative solutions such as pipetting robots and droplet microfluidics. These stated advantages often include a reduction in the required volume of experimental reagents, a reduction in the likelihood of contamination and cross-contamination, potential improvements in reproducibility, increased throughput, individual droplet addressability, and the ability to integrate with sensor and detector modules to perform end-to-end or even closed loop workflow automation.
The Susceptible-Infectious-Recovered-Deceased model differentiates between Recovered (meaning specifically individuals having survived the disease and now immune) and Deceased. The SIRD model has semi analytical solutions based on the four parts method. This model uses the following system of differential equations:
Health Minister Simeon Brown confirms the Government would lower the bowel screening eligibility age range from 60 to 58 years, using funding from a cancelled pilot programme established by the previous Labour government to lower the eligibility age for Māori and Pasifika New Zealanders from 60 to 50 years. Air New Zealand CEO Greg Foran announces that he will resign from his position effective 20 October. 7 March: New Zealand Labour Party leader Chris Hipkins announces a cabinet reshuffle of his shadow cabinet during his State of the Nation speech. Health Minister Simeon Brown announces a major overhaul of Health New Zealand including reinstating its leadership board, decentralisation and promoting private-public partnership. 8 March: A Pride parade is held in Wellington, with Mayor of Wellington Tory Whanau and actor Karen O'Leary attending. About 30 Destiny Church Man Up protesters stage a counter-protest. Police separate the two groups. A total fire ban comes into force in the Northland Region from 12am midnight in response to persistent dry, hot and windy conditions. 11 March – School lunch provider Libelle Group goes into liquidation, affecting 500 staff. The company had been contracted by the Compass Group to provide 125,000 meals to the Government's "Ka Ora, Ka Ako" school meal programme. 12 March: Camilla Belich's Crimes (Theft By Employer) Amendment Bill passes its third reading in Parliament with the support of the Labour, Green, Te Pāti Māori and New Zealand First.
With the goal of mitigating these disadvantages while applying nanotechnology to electronics, researchers at the National Science Foundation's Nanoscale Science and Engineering Center for High-Rate Nanomanufacturing (CHN) at Northeastern University with partners UMass Lowell and University of New Hampshire have developed a directed assembly process of single-walled carbon nano tube (SWNT) networks to create a circuit template that can be transfer from one substrate to another.
=== Adults === The special symptom of OSA syndrome in adults is excessive daytime sleepiness. Typically, an adult or adolescent with severe long-standing OSA will fall asleep for very brief periods in the course of usual daytime activities if allowed to sit or rest. This behavior may be quite dramatic, sometimes occurring during conversations with others at social gatherings. The hypoxia (absence of oxygen supply) related to OSA may cause changes in the neurons of the hippocampus and the right frontal cortex. Neuroimaging research revealed evidence of hippocampal atrophy in people with OSA. They found that OSA can cause problems in mentally manipulating nonverbal information, executive functions, and working memory. OSA may also be associated with an increased risk of a person developing Alzheimer's disease. Obesity is a major risk factor for OSA. In the severely obese, the risk for sleep apnea can be between 55 and 90%. However between 20 and 25% of patients with sleep apnea are not overweight. What is often unrecognized in primary care is that it is crucial to identify these patients because they are four times more likely to develop hypertension than obese individuals without OSA. And non-obese patients are at a higher risk for early atherosclerosis. In fact, approximately 2.7 times more than obese patients without OSA. This risk increases as the severity of the syndrome worsens.
Sources: en.wikipedia.org
Congenital contractural arachnodactyly, also known as Beals–Hecht syndrome Ehlers–Danlos syndrome Homocystinuria Loeys–Dietz syndrome MASS phenotype Multiple endocrine neoplasia, type 2B Shprintzen–Goldberg syndrome Stickler syndrome
Atkins, P. W. Physical Chemistry (Oxford University Press) ISBN 0-19-879285-9 Atkins, P. W. et al. Molecular Quantum Mechanics (Oxford University Press) McWeeny, R. Coulson's Valence (Oxford Science Publications) ISBN 0-19-855144-4 Pauling, L. The Nature of the chemical bond (Cornell University Press) ISBN 0-8014-0333-2 Pauling, L., and Wilson, E. B. Introduction to Quantum Mechanics with Applications to Chemistry (Dover Publications) ISBN 0-486-64871-0 Smart and Moore. Solid State Chemistry: An Introduction (Chapman and Hall) ISBN 0-412-40040-5 Stephenson, G. Mathematical Methods for Science Students (Longman) ISBN 0-582-44416-0
Hydrolysis of peptides of at least six residues, with bulky hydrophobic residues in the P1' position. Shows a preference for hydrophobic doublets such as -Phe-Phe- and -Phe-Leu- in somatostatin-(1-14)-peptide and dynorphin A-(1-6)-peptide, respectively This endopeptidase in the skin of the amphibian, Xenopus laevis.
== Trade names == Tofisopam has been spelt alternatively as tofizopam and has been marketed and listed as ‘’‘Grandaxin’’’ in Hungary and other European countries, Pakistan, and Egypt. Japanese preparations include ‘’‘Grandaxin 10%’’’ and ‘’‘Granpam’’’ It has been marketed in India as ‘’‘Nextril’’’ and ‘’‘Toficalm’’’. Never approved in North America, including the U.S. and Canada, but it has appeared in United States patent literature and regulatory references. A U.S. patent concerning S-tofisopam was filed in 2001 and subsequently issued as U.S. Patent 6,649,607; the related patent record expired in November 2021US 7078398, "Compositions and methods for treating or preventing convulsions or seizures" </ref>
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.